EGFR and cancer: It has been well-established that EGFR is a major oncogenic factor and a promising therapeutic target in certain types of cancers, and many EGFR inhibitors (EGFRis), including monoclonal antibodies and small-molecule tyrosine kinase inhibitors, have been approved by the FDA for the treatment of several human cancers 6, 8.